ACM acquires ABS to accelerate growth driven by clinical trials, toxicology

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/JK1991)
(Image: Getty/JK1991)
ACM Global Laboratories has acquired ABS Laboratories to better serve its clients in the clinical trial market with an expanded "scientific acumen," says company president.

US-headquartered ACM Global Laboratories​ is a wholly-owned subsidiary of Rochester Regional Health.

ABS Laboratories is a GLP bioanalytical lab specializing in assay method development and validation for the quantification of drugs, metabolites, and biomarkers in biological samples for preclinical and clinical trials. 

With the acquisition of ABS, John Foley, acting president of ACM Global Laboratories, said the company is expanding its pharmacokinetic (PK) testing capabilities at its central labs for clinical trials. 

“ABS Labs brings decades of PK testing research and operational expertise to ACM,”​ Foley told us. “These capabilities will help us to better serve our clients in the clinical trial market by broadening our testing catalog and expanding our scientific acumen in this space.”

Foley said ACM’s growth is driven by two of its major market segments: Clinical trials and toxicology. 

“ACM has seen substantial organic growth in both of these markets over the last few years,” ​he added. “We’ve decided to expand our services, capabilities, and geographic footprint to accelerate this growth.”

ABS Labs will remain an independent entity within ACM Global Laboratories, which will retain ABS’ leadership, staff, and facilities.

Related topics: Clinical Development

Related news

Show more